US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
WO1996041606A2
(en)
*
|
1995-06-08 |
1996-12-27 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
FR2741066B1
(fr)
*
|
1995-11-14 |
1997-12-12 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
FR2756491B1
(fr)
*
|
1996-11-29 |
1999-01-08 |
Rhone Poulenc Rorer Sa |
Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
|
FR2750704B1
(fr)
|
1996-07-04 |
1998-09-25 |
Rhone Poulenc Rorer Sa |
Procede de production d'adn therapeutique
|
CN1181422A
(zh)
*
|
1996-10-31 |
1998-05-13 |
上海市肿瘤研究所 |
与生长因子受体结合的多肽所构建的基因转移载体
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
EP0948609B1
(de)
|
1996-12-06 |
2005-03-16 |
Aventis Pharmaceuticals Inc. |
Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
US6638502B1
(en)
|
1997-04-28 |
2003-10-28 |
Gencell Sas |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
FR2763943B1
(fr)
*
|
1997-05-28 |
1999-07-09 |
Rhone Poulenc Rorer Sa |
Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
FR2774394B1
(fr)
*
|
1998-01-30 |
2002-04-26 |
Rhone Poulenc Rorer Sa |
Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
|
EP1049793B1
(de)
|
1998-01-30 |
2005-10-12 |
Aventis Pharma S.A. |
Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
WO2000032803A2
(fr)
*
|
1998-12-03 |
2000-06-08 |
Aventis Pharma S.A. |
Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations
|
FR2786700B1
(fr)
*
|
1998-12-03 |
2002-12-06 |
Aventis Pharma Sa |
Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US9034329B2
(en)
*
|
1999-02-22 |
2015-05-19 |
Georgetown University |
Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
|
CA2362550C
(en)
*
|
1999-02-22 |
2010-05-11 |
Georgetown University |
Antibody fragment-targeted immunoliposomes for systemic gene delivery
|
US7780882B2
(en)
*
|
1999-02-22 |
2010-08-24 |
Georgetown University |
Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
DE69943068D1
(de)
*
|
1999-09-09 |
2011-02-03 |
Curevac Gmbh |
Transfer von mRNA unter Verwendung von polykationischen Verbindungen
|
CA2390716A1
(en)
*
|
1999-09-24 |
2001-04-05 |
Alan D. King |
Process for enhancing electric field-mediated delivery of biological materials into cells
|
ATE511856T1
(de)
|
2000-03-13 |
2011-06-15 |
Cornell Res Foundation Inc |
Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US20040110928A1
(en)
*
|
2000-04-12 |
2004-06-10 |
Andrea Crisanti |
Peptide conjugates for drug delivery
|
US7416726B2
(en)
|
2000-04-13 |
2008-08-26 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
US20040142474A1
(en)
*
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
US6696038B1
(en)
|
2000-09-14 |
2004-02-24 |
Expression Genetics, Inc. |
Cationic lipopolymer as biocompatible gene delivery agent
|
FR2814370B1
(fr)
*
|
2000-09-22 |
2004-08-20 |
Centre Nat Rech Scient |
Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
EP1355918B9
(de)
|
2000-12-28 |
2012-01-25 |
Wyeth LLC |
Rekombinantes schutzprotein aus streptococcus pneumoniae
|
US20030125239A1
(en)
*
|
2001-02-02 |
2003-07-03 |
Andrea Crisanti |
Compositions for drug delivery
|
WO2002063026A1
(en)
*
|
2001-02-08 |
2002-08-15 |
Geneporter, Inc. |
Complexes and components thereof for introducing polynucleotides into eukaryotic cells
|
DK1456346T3
(da)
|
2001-02-20 |
2012-05-29 |
Intrexon Corp |
Nyt inducerbart genekspressionssystem baseret på ecdysonreceptor/invertebrat-retinoid-x-receptor
|
EP3470520A2
(de)
|
2001-02-20 |
2019-04-17 |
Intrexon Corporation |
Neuartige substitution mutanter rezeptoren und deren verwendung in einem auf nuklearen rezeptoren beruhenden induzierbaren genexpressionssystem
|
CA2438119C
(en)
|
2001-02-20 |
2014-12-16 |
Rheogene Holdings, Inc. |
Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
|
EP1534738B1
(de)
|
2001-02-20 |
2012-06-20 |
Intrexon Corporation |
Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionsystem auf grundlage eines nukleären rezeptors
|
DE60234475D1
(de)
|
2001-03-02 |
2009-12-31 |
Univ Rockefeller |
Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
|
US8216585B2
(en)
*
|
2001-05-25 |
2012-07-10 |
The Trustees Of The University Of Pennsylvania |
Targeted particles and methods of using the same
|
EP1399189A1
(de)
*
|
2001-06-11 |
2004-03-24 |
Universite De Montreal |
Mittel und verfahren zur erhöhung des nukleinsäuretransfers in zellen
|
FR2829136B1
(fr)
*
|
2001-08-29 |
2006-11-17 |
Aventis Pharma Sa |
Derives lipidiques d'aminoglycosides
|
MXPA04002808A
(es)
|
2001-09-26 |
2005-06-06 |
Rheogene Holdings Inc |
Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
|
MXPA04002810A
(es)
|
2001-09-26 |
2005-06-06 |
Rheogene Holdings Inc |
Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
DK1479985T3
(en)
|
2002-01-17 |
2017-09-25 |
Alfa Laval Corp Ab |
SUBMITTED EVAPORATOR INCLUDING A PLATE HEAT EXCHANGE AND A CYLINDRICAL HOUSE WHERE THE PLATE HEAT EXCHANGE IS LOCATED
|
US7037520B2
(en)
*
|
2002-03-22 |
2006-05-02 |
Baylor College Of Medicine |
Reversible masking of liposomal complexes for targeted delivery
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
JP4791730B2
(ja)
*
|
2002-09-27 |
2011-10-12 |
パウダージェクト リサーチ リミテッド |
核酸コーティング粒子
|
US20040176282A1
(en)
*
|
2003-01-09 |
2004-09-09 |
Brian Dalby |
Cellular delivery and activation of polypeptide-nucleic acid complexes
|
US7304161B2
(en)
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
WO2005010157A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Cedars-Sinai Medical Center |
Use of pleiotrophin in the diagnosis, treatment and prevention of disease
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
AU2004297533B2
(en)
|
2003-10-24 |
2010-04-29 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
EP2267458A3
(de)
|
2004-04-20 |
2011-04-06 |
Galapagos N.V. |
Verfahren, Zusammensetzungen und Verbindungstests zur Hemmung der Amyloid-beta-proteinproduktion
|
MXPA06012162A
(es)
|
2004-04-27 |
2007-03-30 |
Galapagos Nv |
Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
EP2270160A1
(de)
|
2004-06-14 |
2011-01-05 |
Galapagos N.V. |
Identifizierungsverfahren und Verbindungen für die Behandlung degenerativer und entzündlicher Erkrankungen
|
US7425445B2
(en)
|
2004-06-18 |
2008-09-16 |
Duke University |
Modulators that promote cell surface expression of odorant receptors
|
US20070004658A1
(en)
|
2004-06-21 |
2007-01-04 |
Nick Vandeghinste |
Method and means for treatment of osteoarthritis
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
JP4772045B2
(ja)
|
2004-07-16 |
2011-09-14 |
アメリカ合衆国 |
Cmv/r核酸コンストラクトを含むaidsに対するワクチン
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US7964571B2
(en)
|
2004-12-09 |
2011-06-21 |
Egen, Inc. |
Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
JP5777846B2
(ja)
*
|
2005-06-15 |
2015-09-09 |
マサチューセッツ インスティテュート オブ テクノロジー |
アミン含有脂質およびその使用
|
CN101437539B
(zh)
|
2005-07-05 |
2013-10-02 |
康奈尔研究基金会(有限公司) |
通过干扰cd99l2阻断白细胞迁出和炎症
|
US7666584B2
(en)
|
2005-09-01 |
2010-02-23 |
Philadelphia Health & Education Coporation |
Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
|
WO2007142781A1
(en)
*
|
2006-05-15 |
2007-12-13 |
Georgetown University |
Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
|
KR100857389B1
(ko)
|
2006-06-30 |
2008-09-11 |
(주)아모레퍼시픽 |
Ap-grr 펩티드 또는 ap-grr 펩티드를 포함하는펩티드사슬 및 이를 포함하는 약물전달담체
|
JP2009544731A
(ja)
|
2006-07-28 |
2009-12-17 |
サノフィ−アベンティス |
腫瘍治療のための組成物及び方法
|
EP2069500B1
(de)
*
|
2006-10-04 |
2014-09-24 |
Centre National De La Recherche Scientifique (Cnrs) |
Zusammensetzungen mit einer sirna und lipidischen 4,5-disubstituierten 2-desoxystreptaminring-aminoglykosid-derivaten und verwendungen davon
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2155910A4
(de)
|
2007-05-08 |
2010-06-02 |
Univ Duke |
Zusammensetzungen und verfahren zur charakterisierung und regulierung der geruchswahrnehmung
|
WO2008153801A1
(en)
|
2007-05-29 |
2008-12-18 |
Intrexon Corporation |
Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
EP2565649B1
(de)
|
2007-06-20 |
2015-04-15 |
Galapagos N.V. |
Molekulare Targets und Verbindungen sowie Verfahren zu ihrer Identifizierung für die Behandlung von degenerativen Knochen- und Gelenkserkrankungen
|
US20090069266A1
(en)
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
KR101570886B1
(ko)
*
|
2007-07-09 |
2015-11-23 |
조지타운 유니버시티 |
양이온성-리포솜 매개된 핵산 전달을 이용하여 면역 반응을 생성시키는 방법
|
US9144546B2
(en)
|
2007-08-06 |
2015-09-29 |
Clsn Laboratories, Inc. |
Nucleic acid-lipopolymer compositions
|
CN101835908A
(zh)
|
2007-08-23 |
2010-09-15 |
英特瑞克斯顿股份有限公司 |
诊断疾病的方法和组合物
|
CN101970012A
(zh)
*
|
2007-09-14 |
2011-02-09 |
日东电工株式会社 |
药物载体
|
NZ583992A
(en)
*
|
2007-09-17 |
2012-11-30 |
Rohm & Haas |
A gene expression system for controllable expression of ethylene response in a plant
|
KR101666228B1
(ko)
|
2007-09-28 |
2016-10-13 |
인트렉손 코포레이션 |
생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
|
EP2042193A1
(de)
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA-Impfstoffe
|
RU2484132C2
(ru)
|
2007-10-08 |
2013-06-10 |
Интрексон Корпорейшн |
Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей
|
FR2928373B1
(fr)
|
2008-03-05 |
2010-12-31 |
Centre Nat Rech Scient |
Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
|
WO2010029118A1
(en)
|
2008-09-11 |
2010-03-18 |
Biofocus Dpi B.V. |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
KR20110081282A
(ko)
|
2008-11-05 |
2011-07-13 |
와이어쓰 엘엘씨 |
베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물
|
MX2011004859A
(es)
|
2008-11-07 |
2011-08-03 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
WO2010094734A2
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
JP2012518181A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
US20110306655A1
(en)
|
2009-02-19 |
2011-12-15 |
Richard Antonius Jozef Janssen |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
EP2414830A2
(de)
|
2009-03-31 |
2012-02-08 |
Robert Zimmermann |
Atgl(adipose triglyceride lipase )-modulation zur vorbeugung und behandlung von kachexie, gewichtsverlust und muskelatrophie sowie screening-verfahren dafür
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
JP2012522977A
(ja)
|
2009-04-01 |
2012-09-27 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
変形性関節症の治療のための方法及び手段
|
WO2010120374A2
(en)
|
2009-04-17 |
2010-10-21 |
New York University |
Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
US9186370B2
(en)
|
2010-03-19 |
2015-11-17 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
JP2013527753A
(ja)
|
2010-03-23 |
2013-07-04 |
イントレキソン コーポレーション |
治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
|
KR101594228B1
(ko)
|
2010-08-23 |
2016-02-15 |
와이어쓰 엘엘씨 |
네이세리아 메닌기티디스 rLP2086 항원의 안정한 제제
|
KR101584871B1
(ko)
|
2010-09-10 |
2016-01-22 |
와이어쓰 엘엘씨 |
네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
|
CN103476928B
(zh)
|
2010-12-09 |
2017-03-29 |
巴斯德研究所 |
用于获得高产量重组蛋白表达的基于mgmt的方法
|
EP2492279A1
(de)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
|
JP6189754B2
(ja)
|
2011-03-04 |
2017-08-30 |
イントレキソン コーポレーション |
タンパク質を条件的に発現するベクター
|
CA2831392C
(en)
|
2011-03-28 |
2020-04-28 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
US9458456B2
(en)
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
EP2546358A1
(de)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
|
BR112014006535A2
(pt)
|
2011-09-20 |
2017-03-28 |
Univ North Carolina Chapel Hill |
regulação dos canais de sódio através das proteínas plunc
|
WO2013053765A1
(en)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
KR102272498B1
(ko)
|
2011-10-27 |
2021-07-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
|
JP6215223B2
(ja)
|
2011-12-09 |
2017-10-18 |
アンスティテュ・パストゥール |
マルチプレックス免疫スクリーニングアッセイ
|
WO2013103401A1
(en)
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
MY198910A
(en)
|
2012-03-09 |
2023-10-02 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
EP2698377A1
(de)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
|
US9802987B2
(en)
|
2013-03-08 |
2017-10-31 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
EP2972381A2
(de)
|
2013-03-14 |
2016-01-20 |
Galapagos NV |
Molekulare targets und verbindungen damit, verfahren zur identifikation davon zur verwendung bei der behandlung von erkrankungen im zusammenhang mit epithelial-mesenchymaler transition
|
US9952202B2
(en)
|
2013-03-14 |
2018-04-24 |
Galapagos Nv |
Methods of identifying compounds for the treatment of fibrosis by using S1PR5
|
US20160054304A1
(en)
|
2013-03-14 |
2016-02-25 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
|
RU2637946C2
(ru)
|
2013-03-15 |
2017-12-08 |
Интрексон Корпорейшн |
Борсодержащие диацилгидразины
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
US9840479B2
(en)
|
2014-07-02 |
2017-12-12 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
CA2961738A1
(en)
|
2014-09-17 |
2016-03-24 |
Intrexon Corporation |
Boron-containing diacylhydrazine compounds
|
JP6800863B2
(ja)
|
2015-02-06 |
2020-12-16 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
最適化されたヒト凝固第viii因子遺伝子発現カセットおよびその使用
|
MX2017010705A
(es)
|
2015-02-19 |
2017-12-04 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de la misma.
|
TW201710503A
(zh)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
新穎多核苷酸、載體、醫藥組成物以及其用途
|
LT3310764T
(lt)
|
2015-06-19 |
2023-06-12 |
Massachusetts Institute Of Technology |
Alkenilu pakeisti 2,5-piperazindionai ir jų panaudojimas kompozicijose, skirtose agento pristatymui į subjektą ar ląstelę
|
ES2907486T3
(es)
|
2015-09-24 |
2022-04-25 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para reducir metástasis
|
CA3001590A1
(en)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
EP3419994B1
(de)
|
2016-02-22 |
2024-05-08 |
The University of North Carolina at Chapel Hill |
Peptidinhibitoren von calciumkanälen
|
NZ752941A
(en)
|
2016-11-09 |
2023-04-28 |
Intrexon Corp |
Frataxin expression constructs
|
JP6661797B2
(ja)
|
2016-11-22 |
2020-03-11 |
株式会社東芝 |
核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット
|
US10183070B2
(en)
|
2017-01-31 |
2019-01-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
WO2019110817A1
(en)
|
2017-12-08 |
2019-06-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Bioluminescent screening test for detecting cell cytolysis
|
EP3539975A1
(de)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Mikropeptide und verwendungen davon
|
SG11202101169PA
(en)
|
2018-08-10 |
2021-03-30 |
Eutilex Co Ltd |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
EP3935077A1
(de)
|
2019-03-08 |
2022-01-12 |
Obsidian Therapeutics, Inc. |
Cd40l-zusammensetzungen und verfahren zur abstimmbaren regulierung
|
WO2020212756A2
(en)
|
2019-04-18 |
2020-10-22 |
Genkin Dmitry Dmitrievich |
Reprogramming of polymorphonuclear leukocytes
|
WO2021142376A1
(en)
|
2020-01-08 |
2021-07-15 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
EP3885440A1
(de)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Spaltinteine und deren verwendungen
|
WO2023242436A1
(en)
|
2022-06-17 |
2023-12-21 |
Danmarks Tekniske Universitet |
Allergy vaccines based on consensus allergens
|